Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. (APGE): 9 pipeline candidates · 8 upcoming catalysts · ~56 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
55.8 months
0% dilution
Lead: Phase 2
9 candidates
8 upcoming, next in ~12d
0 buys · 53 sells (180d)
A transparent, data-derived signal for Apogee Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.7B
Cash
$451.8M
Quarterly Burn
$55.6M
Runway
55.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
Upcoming Catalysts (8)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
228
Total value held
$5.67B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 9,262,291 | $779.6M |
| vanguard capital management llc | 5,004,190 | $421.2M |
| janus henderson group plc | 4,721,192 | $397.6M |
| wellington management group llp | 4,375,703 | $368.3M |
| blackrock, inc. | 4,085,651 | $343.9M |
| perceptive advisors llc | 3,080,768 | $259.3M |
| rtw investments, lp | 2,782,097 | $234.2M |
| state street corp | 2,162,964 | $182.1M |
| driehaus capital management llc | 1,920,800 | $161.7M |
| paradigm biocapital advisors lp | 1,348,243 | $113.5M |
Showing top 10 of 228 institutional holders of Apogee Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Apogee Therapeutics, Inc.'s pipeline?
Apogee Therapeutics, Inc. (APGE) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Apogee Therapeutics, Inc.'s lead drug candidate?
Apogee Therapeutics, Inc.'s most advanced tracked candidate is APG222 (Preclinical) for Initially developing for treatment of atopic dermatitis (AD); believed to have potential to impact multiple additional I&I indications..
What is Apogee Therapeutics, Inc.'s next catalyst?
Apogee Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: apg777" — expected June 30, 2026.
What is Apogee Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Apogee Therapeutics, Inc. has approximately 55.8 months of cash runway.
What is Apogee Therapeutics, Inc.'s market capitalization?
Apogee Therapeutics, Inc.'s market capitalization is approximately $6.7B.
Get the full picture on Apogee Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.